Show simple item record

dc.creatorIaconis, Daniela
dc.creatorBordi, Licia
dc.creatorMatusali, Giulia
dc.creatorTalarico, Carmine
dc.creatorManelfi, Candida
dc.creatorCesta, Maria Candida
dc.creatorZippoli, Mara
dc.creatorCaccuri, Francesca
dc.creatorBugatti, Antonella
dc.creatorZani, Alberto
dc.creatorFilippini, Federica
dc.creatorScorzolini, Laura
dc.creatorGobbi, Marco
dc.creatorBeeg, Marten
dc.creatorPiotti, Arianna
dc.creatorMontopoli, Monica
dc.creatorCocetta, Veronica
dc.creatorBressan, Silvia
dc.creatorBucci, Enrico
dc.creatorCaruso, Arnaldo
dc.creatorNicastri, Emanuele
dc.creatorAllegretti, Marcello
dc.creatorBeccari, Andrea R.
dc.identifier.citationIaconis, D., Bordi, L., Matusali, G. et al. Characterization of raloxifene as a potential pharmacological agent against SARS-CoV-2 and its variants. Cell Death Dis 13, 498 (2022).
dc.description.abstractThe new coronavirus SARS-CoV-2 is the causative agent of the COVID-19 pandemic, which so far has caused over 6 million deaths in 2 years, despite new vaccines and antiviral medications. Drug repurposing, an approach for the potential application of existing pharmaceutical products to new therapeutic indications, could be an effective strategy to obtain quick answers to medical emergencies. Following a virtual screening campaign on the most relevant viral proteins, we identified the drug raloxifene, a known Selective Estrogen Receptor Modulator (SERM), as a new potential agent to treat mild-to-moderate COVID-19 patients. In this paper we report a comprehensive pharmacological characterization of raloxifene in relevant in vitro models of COVID-19, specifically in Vero E6 and Calu-3 cell lines infected with SARS-CoV-2. A large panel of the most common SARS-CoV-2 variants isolated in Europe, United Kingdom, Brazil, South Africa and India was tested to demonstrate the drug’s ability in contrasting the viral cytopathic effect (CPE). Literature data support a beneficial effect by raloxifene against the viral infection due to its ability to interact with viral proteins and activate protective estrogen receptor-mediated mechanisms in the host cells. Mechanistic studies here reported confirm the significant affinity of raloxifene for the Spike protein, as predicted by in silico studies, and show that the drug treatment does not directly affect Spike/ACE2 interaction or viral internalization in infected cell lines. Interestingly, raloxifene can counteract Spike-mediated ADAM17 activation in human pulmonary cells, thus providing new insights on its mechanism of action. A clinical study in mild to moderate COVID-19 patients (NCT05172050) has been recently completed. Our contribution to evaluate raloxifene results on SARS-CoV-2 variants, and the interpretation of the mechanisms of action will be key elements to better understand the trial results, and to design new clinical studies aiming to evaluate the potential development of raloxifene in this indication.
dc.format.extent9 pages
dc.relation.ispartofCOVID-19 Research
dc.relation.haspartCell Death & Disease, Vol. 13
dc.relation.isreferencedbySpringer Nature
dc.rightsAttribution CC BY
dc.subjectPreclinical research
dc.subjectViral infection
dc.titleCharacterization of raloxifene as a potential pharmacological agent against SARS-CoV-2 and its variants
dc.type.genreJournal article
dc.contributor.groupSbarro Health Research Organization (Temple University)
dc.ada.noteFor Americans with Disabilities Act (ADA) accommodation, including help with reading this content, please contact
dc.description.schoolcollegeTemple University. College of Science and Technology
dc.temple.creatorBucci, Enrico

Files in this item


This item appears in the following Collection(s)

Show simple item record

Attribution CC BY
Except where otherwise noted, this item's license is described as Attribution CC BY